Evaluation of Enzymatic changes in cholestasis index and TGF-β expression in cholestatic rat's liver were treated with ethanolic extract of Epimedium

Subject Areas : Journal of Comparative Pathobiology

فاطمه Karimi, ¹ , پژمان Mortazavi, ² , A. Asghari, ³

1 - Graduated of veterinary medicine, faculty of veterinary medicine, science and research branch, Islamic azad university, Tehran, Iran
2 - Department of pathobiology, faculty of veterinary medicine, science and research branch, Islamic azad university, Tehran, Iran
3 - Department of Clinical science, faculty of veterinary medicine, science and research branch, Islamic azad university, Tehran, Iran

Received: 2022-02-23 Accepted : 2022-02-23 Published : 2021-08-23

Keywords: Rats, Cholestasis, Fibrosis, Epimedium, ALP, TGF-β,

Abstract :

Liver fibrosis is one of the chronic and common diseases that is associated with increased production of excess collagen in the liver by star-shaped cells with increased TGF-β expression. Induction of cholestasis is one way which caused to liver fibrosis. The aim of the present study was to evaluate the antifibrotic effect of Epimedium extract on liver cholestasis induced by bile duct ligation (BDL) in rats. In this study, 40 male Wistar rats weighing 200-250 g were used. The rats were divided into 8 groups of 5, including healthy control, 3 healthy experimental were treated with doses of 100, 200 and 400 mg/kg of Epimedium extract, BDL group and 3 BDL were treated with mentioned doses. The rats were treated via intragastric gavage for 45 consecutive days (once per day). After 45 days, Alkalin phosphatase serumic level was measured after rats anesthesia and their serum isolation. Also, the rat's liver was fixed, colored and then evaluated via using the common immunohistochemical method with TGF-β antibody.The results showed a significant increase in serum levels of ALP enzyme and an increase in TGF-β expression in BDL group. Dose-dependent Treatment with Epimedium extract was able to improve these changes significantly. The results of this study showed that Epimedium extract probably improves the serum level of ALP enzyme by increasing the stability of cell membranes and also reduces the production and deposition of collagen in the liver by inhibiting the activation of stellar cells and inhibiting TGF-β expression. 

References:

1. Tomur A, KantermM, Gurel A, Erboga M. The efficiency of CAPE on retardation of hepatic fibrosis in biliary obstructd rats. G Mol Histol. 2011; 42(5):451-8.


2. Tag CG, Weiskirchen S, Hittatiya K, Tacke F, Tolba RH, Weiskirchen R. Induction of experimental obstructive cholestasis in mice. Laboratory animals. 2015;49(51): 70-80


3. Biernacka A, Dobaczewski M, Frangogiannis N.G. TGF-β signaling in fibrosis. PMC. 2011; 29(5): 196-202.


4. Yanguas S, Cogliati B, Willebrords J, Maes M, Colle I, van den Bossche B, Oliveira C, Andraus W, Alves V Leclercq L, Vinken M. Experimental models of liver fibrosis. PMC. 2016;90(5): 1025-1048.


5. Chen WY, Chen CJ, Liao JW, Mao FC. Chromium attenuates hepatic damage in a rat model of chronic cholestasis. Life Sci 2009;84:606–14.


6. Shah R, John S. Cholestatic Jaundice (Cholestasis, Cholestatic Hepatitis). In: StatPearls. StatPearls Publishing, Treasure Island (FL); 2019.


7. Kenneth S. Latimer. Duncan & Prasse's Veterinary Laboratory Medicine Clinical PATHOLOGY. Fifth edition. 2011.


8. Meng FH, Li YB, Xiong ZL, Jiang ZM, Li FM. Osteoblastic proliferative activity of Epimedium brevicornum Maxim. Phytomedicine. 2005 Mar 22;12(3):189-93.


9. Mormone E, George J, Nieto N. Molecular pathogenesis of hepatic fibrosis and current therapeutic approaches. Chem Biol Interact 2011:193:225_31.


10. Morry J, Ngamcherdtrakul Worapol, Yantasee W. Oxidative stress in cancer and fibrosis: Opportunity for therapeutic intervention with antioxidant compounds, enzymes, and nanoparticles. Elsevier. Redix Biology. 2017;11:240-253.


11. Lu Y, Wang D, Hu Y, Huang X, Wang J. Sulfated modification of Epimedium polysaccharide and effects of the modifiers on cellular infectivity of IBDV. Carbohydrate Polymers. 2008 Jan 24;71(2):180-6.


12. Perez MJ, Briz O. Bile-acids-induced cell injury and protection. World J Gastroenterol. 2009; 15(14): 1677-1689.

 

13. Lee MK, Choi YJ, Sung SH, Shin DI, Kim JW, Kim YC. Antihepatotoxic activity of icariin, a major constituent of Epimedium koreanum. Planta medica. 1995 Dec;61(06):523-6.


14. Cohen I, inventor; Bionovo Inc, assignee. Method of using extracts of Epimedium species. United States patent application US 11/298,957. 2006 Jun 22.


15. Fan Y, Lu Y, Wang D, Liu J, Song X, Zhang W, Zhao X, Nguyen TL, Hu Y. Cell Immunol. 2013 Jan;281(1):37-43. doi: 10.1016/j.cellimm.2013.01.008. Epub 2013 Feb 4..


16. Fang J, Zhang Y. Icariin, an anti-atherosclerotic drug from chinese medicinal herb horny goat weed. Frontiers in pharmacology. 2017 Oct 12;8:734.


17. Jung YY, Lee JH, Nam D, Narula AS, Namjoshi OA, Blough BE, Um JY, Sethi G, Ahn KS. Anti-myeloma effects of icariin are mediated through the attenuation of jak/stat3-dependent signaling cascade. Frontiers in pharmacology. 2018 May 30;9:531.

18. Wang L, Li S, Wang HY, Zeng J, Zhang ZZ, Lv DY, Kuang WH.Evid Based Complement Alternat Med. 2019 Nov 7;2019:4253846. doi: 10.1155/2019/4253846. eCollection 201.